ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Allogeneic Anti-CD19/CD20 CAR T-cells AVC-203

Its studies are mostly in Lymphoma, Large B-Cell, Diffuse, led by AvenCell Therapeutics.

Furthest: phase 2, since Nov 25, 20251 company-led study, 1 open or runningNext primary completion: Apr 27, 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AvenCell Therapeutics11 open or runningphase 2since Nov 25, 2025Nov 25, 2025Apr 27, 2029phase 2 · NCT07284433

Also a collaborator on its studies: AvenCell Europe.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 25, 2025First study: phase 2 study in Lymphoma, Large B-Cell, DiffuseFirst studyNCT07284433 · 178 planned · United States, Germany

Ahead

  1. Apr 27, 2029Primary completion: phase 2 study in Lymphoma, Large B-Cell, DiffuseNCT07284433

TargetBeta

CD19 →MS4A1 →read by rule
“An off-the-shelf (OTS) preparation of human allogeneic T-lymphocytes genetically modified to express a chimeric antigen receptor (CAR) specific for both the tumor-associated antigen (TAA) CD19 and the TAA CD20, and clustered regularly interspaced short palindromic repeats (”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
rondecabtagene autoleucelrulelyell-immunopharma-incphase 32
zamtocabtagene autoleucelrulemiltenyi-biomedicine-gmbhphase 28
Autologous Anti-CD19/CD20 CAR-T Cells KITE-363ruleGilead Sciencesphase 23
prizloncabtagene autoleucelruleAbelZetaphase 22
GSK5926371GlaxoSmithKlinephase 22
CT204V-CD19 × CD20ruleAstraZenecaphase 21
HB2198rulehinge-biophase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07284433Lymphoma, Large B-Cell, Diffuse · United States, Germany2RecruitingApr 27, 2029178

How it is read

Names in the registry

  • “Allo-QuadCAR01-T”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.